Highlights from the prostate cancer genome report
Highlights from the prostate cancer genome report作者机构：Center for Prostate Disease Research Department of Surgery Uniformed Services University of the Health Sciences Rockville MD 20852 USA
出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)
年 卷 期：2011年第13卷第5期
页 面：659-660页
核心收录：
学科分类：0710[理学-生物学] 0819[工学-矿业工程] 081903[工学-安全技术及工程] 07[理学] 08[工学] 09[农学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种]
主 题：Highlights effective therapies
摘 要：Prostate cancer （CAP） is the second most frequently diagnosed cancer of men worldwide （899 000 new cases, 13.6% of the total）, with nearly 75% of the registered cases occurring in developed countries （644 000 cases）.1 Blood prostate-specific antigen test has revolutionized the early detection of CaP and organ-confined CaP is effectively managed by state-of-the-art treatments including radical prostatectomy or radiation therapy.2 In the past decade, tremendous progress has also been made in our understanding of the biology and common genomic alterations in CaP.3＇4 New molecular marker assays have promise in improving CaP diagnosis.5-8 Despite these advances, major challenges remain with our ability to distinguish indolent cancers from the more aggressive cancers detected early due to widely used prostate-specific antigen test. Furthermore, development of molecular stratification of CaP for targeted and more effective therapies is critically needed.
维普期刊数据库